Alexander Mark Schobel - Mar 8, 2024 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Signature
/s/ Lori Braender, as Attorney-In-Fact
Stock symbol
AQST
Transactions as of
Mar 8, 2024
Transactions value $
-$158,453
Form type
4
Date filed
3/12/2024, 01:45 PM
Previous filing
Mar 11, 2024
Next filing
Oct 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Sale -$130K -25K -2.35% $5.19 1.04M Mar 8, 2024 Direct F1, F2
transaction AQST Common Stock Tax liability -$28.8K -5.9K -0.57% $4.88 1.03M Mar 9, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4 on December 16, 2023.
F2 Represents the weighted average sales price per share. The shares sold at prices ranging from $5.00 to $5.60 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.